TRDA Entrada Therapeutics, Inc.
Distress ·
The board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027.
Entrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines that engage intracellular targets through a proprietary endosomal escape vehicle. Its main franchise targets Duchenne muscular dystrophy (DMD) through ENTR-601 programs for exon skipping. ENTR-601-44 and ENTR-601-45 are in global Phase 1/2 trials, and an authorization was received in the United Kingdom for a Phase 1/2 study of ENTR-601-50. The company plans to submit regulatory applications for ENTR-601-51 in 2026. The partnership with Vertex Pharmaceuticals for VX-670 targets myotonic dystrophy type 1, with dosing completion anticipated in mid-2026. The company also has two ocular programs in lead optimization for inherited retinal diseases, and its first ocular clinical candidate, ENTR-801, is aimed at Usher syndrome type 2A. The text estimates that over 11,500 patients in the U.S. and Europe carry mutations amenable to its current exon skipping programs.
| Product or program | What it is | Stage |
|---|---|---|
| ENTR-601-44 | Oligonucleotide-based exon 44 skipping therapy for Duchenne muscular dystrophy | Phase 1/2 global trial, dosing ongoing |
| ENTR-601-45 | Oligonucleotide-based exon 45 skipping therapy for Duchenne muscular dystrophy | Phase 1/2 global trial, patient dosing initiated |
| ENTR-601-50 | Exon 50 skipping therapy for Duchenne muscular dystrophy | Phase 1/2 study authorized in the UK |
| ENTR-601-51 | Duchenne muscular dystrophy program with regulatory submissions planned | Regulatory submissions expected in 2026 |
| VX-670 | Partnered with Vertex for myotonic dystrophy type 1 | Phase 1/2 global trial, MAD portion being dosed |
| ENTR-801 | Ocular oligonucleotide therapy for Usher syndrome type 2A | First ocular clinical candidate |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $25.4 million | $210.8 million |
| Research and development | $142.3 million | $125.3 million |
| Net income (loss) | -$143.8 million | $65.6 million |
| Cash from operations | -$128.5 million | -$41.6 million |
| Cash and equivalents | $90.4 million | $101.2 million |
Entrada Therapeutics, Inc. trades under the ticker TRDA on NASDAQ.
Entrada Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Entrada Therapeutics, Inc. is 1689375. Its filings are on SEC EDGAR.
38,936,669 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Entrada Therapeutics, Inc. under United States.
Our directory classifies Entrada Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Entrada Therapeutics, Inc. is US29384C1080.
aibio.space lists Entrada Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines that engage intracellular targets through a proprietary endosomal escape vehicle. Its main franchise targets Duchenne muscular dystrophy (DMD) through ENTR-601 programs for exon skipping.
ENTR-601-44: Oligonucleotide-based exon 44 skipping therapy for Duchenne muscular dystrophy Stage: Phase 1/2 global trial, dosing ongoing.
ENTR-601-45: Oligonucleotide-based exon 45 skipping therapy for Duchenne muscular dystrophy Stage: Phase 1/2 global trial, patient dosing initiated.
$25.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Entrada Therapeutics, Inc. reported a net loss of $143.8 million for the fiscal year ended Dec 31, 2025, and used $128.5 million of cash in operations, per its annual report to the SEC.
$142.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio